Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 149, Issue 1, 2015, Pages 171-179

  Clemens, Michael R ^a   Gladkov, Oleg A ^b   Gartner, Elaina ^c   Vladimirov, Vladimir ^d   Crown, John ^e   Steinberg, Joyce ^f   Jie, Fei ^f   Keating, Anne ^f  

^a Klinikum Mutterhaus de Borromaerinnen GmbH   (Germany)

^b Chelyabinsk Regional Clinical Oncology Dispensary   (Russian Federation)

^c WAYNE STATE UNIVERSITY   (United States)

^d Pyatigorsk Interdistrict Oncological Dispensary   (Russian Federation)

^e Ireland Cooperative Oncology Research Group ICORG   (Ireland)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

HER2; Metastatic breast cancer; Survivin; YM155

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; CYTOKERATIN 18; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; NITROGEN; SEPANTRONIUM BROMIDE; UREA; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; NAPHTHOQUINONE; TAXOID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE PAIN; BRAIN INFARCTION; BREAST CANCER; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CELLULITIS; CEREBROVASCULAR ACCIDENT; CLINICAL BENEFIT RATE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DURATION OF RESPONSE; DYSGEUSIA; DYSPNEA; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HERPES ZOSTER; HUMAN; HYDRONEPHROSIS; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTIOUS ARTHRITIS; INSOMNIA; LEUKOCYTE COUNT; LEUKOPENIA; LIMB PAIN; LIVER FAILURE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NECK PAIN; NEUTROPENIA; NEUTROPHIL COUNT; OBJECTIVE RESPONSE RATE; OPEN STUDY; OROPHARYNX PAIN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PELVIC PAIN; PERICARDITIS; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PLEURISY; PNEUMONIA; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SPINE FRACTURE; STOMATITIS; SUPERIOR CAVA VEIN OBSTRUCTION; SURVIVAL TIME; T WAVE INVERSION; THROMBOCYTE ANOMALY; THROMBOSIS; TIME TO RESPONSE; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; WOUND INFECTION; ADVERSE DRUG REACTION; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMIDAZOLES; LYMPHATIC METASTASIS; MIDDLE AGED; NAPHTHOQUINONES; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME;

EID: 84925464702     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3238-6     Document Type: Article

References (27)

1. Global Cancer Facts & Figures. (2011) American Cancer Society. Available via http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf. Accessed 22 May 2014
2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29
3. Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9:606–616
4. About Breast Cancer: Stages 0 and 1 (2012) National Breast Cancer Foundation, Inc. Available via http://www.nationalbreastcancer.org/breast-cancer-stage-0-and-stage-1. Accessed 15 May 2014
5. Most common statistics cited for MBC (2014) Metastatic Breast Cancer Network. Available via http://mbcn.org/education/category/most-commonly-used-statistics-for-mbc. Accessed 15 May 2014
6. O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242
8. Chia SK, Speers CH, D’Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’Reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979
9. Breast Cancer Facts and Figures 2013–2014 (2013) American Cancer Society, Inc. Available via http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-042725.pdf. Accessed 15 May 2014
10. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ, 10th St. Gallen Conference (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144
11. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Breast Cancer Version 2. (2014) http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 Apr 2014
12. Eiermann W, International Herceptin Study Group (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 12(Suppl 1):S57–S62
13. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334
14. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70
15. Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill AD, McDermott E, O’Higgins N, Duffy MJ (2005) Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92:120–124
16. Song J, Su H, Zhou YY, Guo LL (2013) Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol 34:2053–2062
17. Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H, Sasamata M (2011) YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol 39:569–575
18. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584
19. Kaneko N, Yamanaka K, Kita A, Tabata K, Akabane T, Mori M (2013) Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells. Biol Pharm Bull 36:1921–1927
20. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198–5203
21. Steinberg J (2009) YM155: a novel small-molecule survivin suppressant. Paper presented at novel therapeutic targets for breast cancer workshop at breast cancer congress, Maui, 2009
22. ® (docetaxel) (2013) Full prescribing information. Sanofi-Aventis US LLC, Bridgewater
23. Lewis KD, Samlowski W, Ward J, Catlett J, Cranmer L, Kirkwood J, Lawson D, Whitman E, Gonzalez R (2011) A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29:161–166
24. Oakman C, Viale G, Di Leo A (2010) Management of triple negative breast cancer. Breast 19:312–321
25. Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, Xin G, Pei L, Gu S, Li X, Zhao X (2014) Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol 2:245–251
26. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67:8014–8021
27. Ryan B, O’Donovan N, Browne B, O’Shea C, Crown J, Hill AD, McDermott E, O’Higgins N, Duffy MJ (2005) Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92:120–124